IBDEI16F ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20009,0)
 ;;=D62.^^84^929^18
 ;;^UTILITY(U,$J,358.3,20009,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20009,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,20009,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,20009,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,20010,0)
 ;;=C92.41^^84^929^19
 ;;^UTILITY(U,$J,358.3,20010,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20010,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,20010,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,20010,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,20011,0)
 ;;=C92.40^^84^929^20
 ;;^UTILITY(U,$J,358.3,20011,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20011,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,20011,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,20011,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,20012,0)
 ;;=D56.0^^84^929^21
 ;;^UTILITY(U,$J,358.3,20012,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20012,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,20012,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,20012,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,20013,0)
 ;;=D63.1^^84^929^23
 ;;^UTILITY(U,$J,358.3,20013,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20013,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,20013,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,20013,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,20014,0)
 ;;=D63.0^^84^929^24
 ;;^UTILITY(U,$J,358.3,20014,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20014,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,20014,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,20014,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,20015,0)
 ;;=D63.8^^84^929^22
 ;;^UTILITY(U,$J,358.3,20015,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20015,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,20015,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,20015,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,20016,0)
 ;;=C22.3^^84^929^26
 ;;^UTILITY(U,$J,358.3,20016,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20016,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,20016,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,20016,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,20017,0)
 ;;=D61.9^^84^929^27
 ;;^UTILITY(U,$J,358.3,20017,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20017,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,20017,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,20017,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,20018,0)
 ;;=D56.1^^84^929^29
 ;;^UTILITY(U,$J,358.3,20018,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20018,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,20018,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,20018,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,20019,0)
 ;;=C83.79^^84^929^31
 ;;^UTILITY(U,$J,358.3,20019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20019,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,20019,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,20019,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,20020,0)
 ;;=C83.70^^84^929^32
 ;;^UTILITY(U,$J,358.3,20020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20020,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,20020,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,20020,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,20021,0)
 ;;=D09.0^^84^929^39
 ;;^UTILITY(U,$J,358.3,20021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20021,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,20021,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,20021,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,20022,0)
 ;;=D06.9^^84^929^40
